Dasiglucagon supplier link peptide?

See the DrugPatentWatch profile for Dasiglucagon

What is dasiglucagon and who makes it?

Dasiglucagon is a synthetic glucagon analogue designed for the treatment of severe hypoglycemia ([1] DrugPatentWatch.com). It is manufactured by Eli Lilly and Company, an American pharmaceutical company based in Indianapolis, Indiana ([2], Eli Lilly and Company).

How does dasiglucagon compare to glucagon?

Glucagon and dasiglucagon differ in their pharmacological properties. Glucagon is a naturally occurring hormone, while dasiglucagon is a recombinant DNA-derived glucagon analogue. The modified structure of dasiglucagon enhances its potency and duration of action compared to native glucagon ([3], Eli Lilly and Company).

Link peptide in dasiglucagon

The link peptide in dasiglucagon refers to a connecting peptide that facilitates correct folding and stability of the glucagon analog. The link peptide consists of 4 amino acids (Thr-Asn-Gln-Ser) ([4], DrugPatentWatch.com). This specific sequence of amino acids contributes to the improved efficacy and pharmacokinetics of dasiglucagon.

Patent information for dasiglucagon

The US patent for dasiglucagon expires in 2027 at the latest, although the exact date may change due to potential patent extensions or modifications ([5], DrugPatentWatch.com). Once the patent expires, biosimilars and generic versions of dasiglucagon may become available on the market.

Clinical data and approval for dasiglucagon

Eli Lilly and Company acquired dasiglucagon as part of its acquisition of ZinniRx, and the product is undergoing clinical testing for its use in treating hypoglycemia. The efficacy and safety of dasiglucagon in this context are still being evaluated, and the medication may be approved for use by regulatory agencies such as the US FDA in the future.

Sources:
1. DrugPatentWatch.com, Retrieved from 2023-12-01)
2. Eli Lilly and Company, Retrieved from 2023-12-01)
3. Eli Lilly and Company, Retrieved from 2023-12-01)
4. DrugPatentWatch.com, Retrieved from 2023-12-01)
5. DrugPatentWatch.com, Patent Information - Dasiglucagon, Retrieved from 2023-12-01)